Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis

Recent years have observed the emergence of novel therapeutic opportunities for advanced hepatocellular carcinoma (HCC), such as combination therapies including immune checkpoint inhibitors. We performed a meta-analysis with the aim to compare median overall survival (OS), median progression-free su...

Descripción completa

Detalles Bibliográficos
Autores principales: Rizzo, Alessandro, Ricci, Angela Dalia, Fanizzi, Annarita, Massafra, Raffaella, De Luca, Raffaele, Brandi, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858216/
https://www.ncbi.nlm.nih.gov/pubmed/36661706
http://dx.doi.org/10.3390/curroncol30010057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858216/
https://www.ncbi.nlm.nih.gov/pubmed/36661706
http://dx.doi.org/10.3390/curroncol30010057

Ejemplares similares